Abstract
Improved remission rates of 70%–80% in childhood acute nonlymphocytic leukemia (ANLL) have been achieved by several groups. Anthracyclines (daunorubicin, doxorubicin) are of great value in the treatment of ANLL. Protocols effective for ANLL commonly include combinations with cytosine arabinoside [1–3]. Aclarubicin, a new alternative anthracycline antibiotic, has proven efficacy in relapsed or advanced as well as in untreated ANLL in adults [4–6]. In 1984 a cooperative multicenter study (AML-IGCI-84) was initiated which incorporated aclarubicin in the first-line therapy of previously untreated childhood ANLL.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
Creutzig U, Ritter J, Budde M, Riehm H, Henze G, Lampert F, Gerein V, Müller-Weihrich S, Niethammer D, Spaar HJ, Schellong G (1986) Aktuelle Ergebnisse der kooperativen AML-Therapiestudien bei Kindern: BFM-78 und -83. Klin Pädiatr 198: 183–190
Weinstein HJ, Mayer RJ, Rosenthal DS, Camitta BM, Coral FS, Nathan DG, Frei E III (1980) Treatment of acute myelogenous leukemia in children and adults. N Engl J Med 303 (9): 473–478
Gale RP, Foon KA (1988) Daunorubicin or doxorubicin in acute myelogenous leukemia? Leukemia 2 (4): 209–210
Pedersen-Bjergaard J, Bricker H, Ellegaard J, Drivsholm A, Freund L, Jensen KB, Jensen MK, Nissen N (1984) Aclarubicin in the treatment of acute nonlymphocytic leukemia refractory to treatment with daunorubicin and cytarabine: a phase II trial. Cancer Treat Rep 68: 1233–1238
Rowe JM, Chang AYC, Bennett JM (1988) Aclacinomycin A and etoposide (VP-16-213): an effective regimen in previously treated patients with refractory acute myelogenous leukemia. Blood 71 (4): 992–996
Hansen OP, Ellegaard J, Madsen PB, Brincker H, Christensen BE, Killmann SA, Laursen ML, Karle H, Drivsholm A, Jensen MK, Laursen B, Jans H, Hippe E, Pedersen-Bjergaard J, Nissen N, Thorling K, Jensen KB (1988) Combination chemotherapy with aclarubicin plus cytosine arabinoside versus daunorubicin plus cytosine arabinoside in de- novo acute myelocytic leukemia. A Danish national trial. Proc Am Assoc Cancer Res Am Soc Clin Oncol 7: 175 (abstract no 675)
Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DAG, Gralnick HR, Sultan C (1976) Proposals for the classification of the acute leukemias. French-American-British ( FAB) cooperative groups. Br J Haematol 33: 451–458
Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DAG, Gralnick HR, Sultan C (1985) Criteria for the diagnosis of acute leukemia of megakaryocytic lineage (M7). A report of the French-American-British cooperative group. Ann Intern Med 103: 460
Creutzig U, Hofmann J, Ritter J, Schellong G (1988) Therapierealisierung und Komplikationen in der Therapiestudie BFM-83 für die akute myeloische Leukämie. Klin Pädiatr 200: 190–199
Dantchev D, Slioussartchouk V, Paintrand M, Hayat M, Bournet C, Mathe G (1979) Electron microscopic studies of the heart and light microscopic studies of the skin after treatment of golden hamsters with adriamycin, detorubicin, AD-32 and aclacinomycin. Cancer Treat Rep 63: 875–888
Warreil RP Jr (1986) Aclacinomycin A: clinical development of a novel anthracycline antibiotic in the haematological cancers. Drugs Exp Clin Res 12 (1/2/3): 275–282
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1990 Springer-Verlag Berlin Heidelberg
About this paper
Cite this paper
Fink, F.M. et al. (1990). Treatment of Childhood Acute Nonlymphocytic Leukemia: Cooperative Austrian-Hungarian Study AML-IGCI-84. In: Büchner, T., Schellong, G., Hiddemann, W., Ritter, J. (eds) Acute Leukemias II. Haematology and Blood Transfusion / Hämatologie und Bluttransfusion, vol 33. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-74643-7_42
Download citation
DOI: https://doi.org/10.1007/978-3-642-74643-7_42
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-50984-4
Online ISBN: 978-3-642-74643-7
eBook Packages: Springer Book Archive